On Thursday, Shares of Skyworks Solutions Inc (NASDAQ:SWKS), lost -3.70% to $74.63.
Skyworks Solutions, declared that it received the 2015 National Export Award (PNE) from Mexico. The PNE is one of four national awards given by Mexico’s federal government recognizing companies, educational institutions and organizations whose efforts have contributed to strengthening Mexico’s competitiveness in international markets. Specifically, Skyworks was recognized for being a role model of innovation and efficiency in delivering high value products to global markets. This is the third successive award for Skyworks from Mexico’s federal government. In 2013, Skyworks received the National Quality Award and in 2014 was awarded the National Technology and Innovation Award.
“Skyworks is honored to receive Mexico’s highest distinction for its world class operations and export capabilities,” said Bruce Freyman, executive vice president of worldwide operations at Skyworks. “Skyworks’ Mexicali facility plays a key role in the assembly, test and packaging of our industry leading analog and RF solutions that are connecting everyone and everything all the time. This award reflects the outstanding commitment from our employees who embrace quality, innovation and productivity on a daily basis.”
Skyworks Solutions, Inc., together with its auxiliaries, designs, develops, manufactures, and markets analog and mixed signal semiconductors worldwide. Its product portfolio comprises amplifiers, attenuators, battery chargers, circulators, DC/DC converters, demodulators, detectors, diodes, directional couplers, filters, front-end modules, hybrids, infrastructure radio frequency subsystems, isolators, LED drivers, mixers, modulators, optocouplers, optoisolators, phase shifters, phase locked loops/synthesizers/VCOs, power dividers/combiners, power administration devices, receivers, switches, technical ceramics, and voltage regulators.
Shares of Geron Corporation (NASDAQ:GERN), declined -2.50% to $3.51, during its last trading session.
Geron Corporation, will declare its financial results for the third quarter ended September 30, 2015, on Thursday, November 5, 2015, after the market close. Geron’s administration will also host a conference call for analysts and investors on Thursday, November 5, 2015, at 4:30 p.m. Eastern Time to discuss the company’s third quarter results and recent events.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies.
Finally, Shares of Express Scripts Holding Company (NASDAQ:ESRX), ended its last trade with 1.82% gain, and closed at $87.15.
Express Scripts Holding Company, declared 2015 third quarter net income attributable to Express Scripts stockholders of $661.7 million, or $0.97 per diluted share. Adjusted earnings per diluted share, as detailed in Table 4, were $1.45 for the third quarter.
“With the rising cost of prescription drugs, we are ongoing our mission to make medicine more affordable and accessible for clients and patients,” said George Paz, Chairman and CEO. “Our innovative solutions, focused scale, specialized care and unmatched leadership manages cost more favorably for payers while improving health outcomes of our patients. Effective pharmacy benefit administration has never been more critical to ensuring a cost-effective healthcare system in our country, and Express Scripts uniquely delivers.”
Third Quarter 2015 Review
The following compares third quarter 2015 and 2014 operating results:
- Adjusted claims of 328.3 million, flat – See Table 1
- Adjusted EBITDA of $1,808.3 million, up 4% – See Table 3
- Adjusted EBITDA per adjusted claim of $5.51, up 4% – See Table 3
- GAAP net income of $661.7 million, up 14%
- Adjusted net income of $989.8 million, up 3% – See Tables 5 and 5A
- GAAP diluted earnings per share of $0.97, up 24%
- Adjusted diluted earnings per share of $1.45, up 12% - See Table 4
- Net cash flow offered by operating activities of $793.0 million, up 82%
Express Scripts Holding Company operates as a pharmacy benefit administration (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations.